Curcumin Upregulates miR-148a to Increase the Chemosensitivity of CD44-Positive Prostate Cancer Stem Cells to Paclitaxel Through Targeting the MSK1/IRS1 axis
- 22 July 2022
- journal article
- research article
- Published by Georg Thieme Verlag KG in Drug Research
- Vol. 72 (08) , 457-465
Abstract
Background In men, prostate cancer (PC) is the second most common cause of cancer-related death. However, paclitaxel resistance is a major challenge in advanced PC. Curcumin, a natural antioxidant, has been demonstrated to have cytotoxic effects on cancer stem cells (CSCs). The goal of this study is to explore if curcumin can help lower chemoresistance to paclitaxel through the regulation of miR-148a-mediated apoptosis in prostate CSCs. Methods The 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay and 4′,6-diamidino-2-phenylindole (DAPi) labeling were used to determine cell survival. Immunohistochemistry was used to detect the expression of P-glycoprotein protein (P-gp) and CD44 proteins. Finally, real-time PCR was used to evaluate the regulatory effects of curcumin and paclitaxel on miR-148a and its target genes. Results Curcumin and paclitaxel co-treatment significantly reduced the IC50 value in CD44+cells compared to paclitaxel alone. Additionally, combining these drugs considerably increased apoptosis in CD44+cells. We also discovered that when curcumin and paclitaxel were combined, the expression of CD44 and P-gp was significantly reduced compared to paclitaxel alone. Curcumin and paclitaxel co-treatment also increased miR-148a levels and regulated the levels of its target genes MSK1 and IRS1. Conclusion Curcumin may restore paclitaxel sensitivity by raising miR-148a expression and inhibiting its target genes. Received: 08 April 2022 Accepted: 30 May 2022 Article published online: 22 July 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
This publication has 37 references indexed in Scilit:
- Curcumin enhances the effectiveness of cisplatin by suppressing CD133+ cancer stem cells in laryngeal carcinoma treatmentExperimental and Therapeutic Medicine, 2013
- Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferationOncology Reports, 2011
- Prostate cancer stem cells and their potential roles in metastasisJournal of Surgical Oncology, 2011
- The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44Nature Medicine, 2011
- MiR-148a Attenuates Paclitaxel Resistance of Hormone-refractory, Drug-resistant Prostate Cancer PC3 Cells by Regulating MSK1 ExpressionJournal of Biological Chemistry, 2010
- Risk factors for prostate cancer incidence and progression in the health professionals follow‐up studyInternational Journal of Cancer, 2007
- Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCRActa Pharmacologica Sinica, 2005
- The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in CancerCancer Research, 2005
- CD133, a novel marker for human prostatic epithelial stem cellsJournal of Cell Science, 2004
- Therapeutic potential of curcumin in prostate cancer—IV: Interference with the osteomimetic properties of hormone refractory C4‐2B prostate cancer cellsThe Prostate, 2003